López-González GJD, Aguilar JMP, Rosales CA

Idioma: Español
Referencias bibliográficas: 11
Paginas: 99-103
Archivo PDF: 201.85 Kb.

RESUMEN

El trastorno mineral-óseo asociado a la enfermedad renal crónica (CKD-MBD) se caracteriza por presentar complicaciones a nivel óseo y cardiovascular. Se presenta en enfermos nefrópatas con escasa adherencia al tratamiento. Presentamos un caso clínico que sufrió dos complicaciones asociadas a esta entidad: osteítis fibrosa quística e ictus por embolismo cálcico, las cuales describimos. Con un manejo adecuado se reduce drásticamente su incidencia, por lo que resulta fundamental la vigilancia estrecha y seguimiento activo de los pacientes.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Moe S, et al. Definition, evaluation, and classification ofrenal osteodystrophy: a position statement from kidneydisease: Improving Global Outcomes (KDIGO).Kidney Int, 69 (2006), pp. 1945-1953.

2. De Francisco AL, Gillespie IA, Gioni I, Floege J,Kronenberg F, Marcelli D, Wheeler DC, FroissartM, Drueke TB; ARO Steering CommitteeCllaborators. Anti-parathyroid treatment effectivenessand persistence in incident haemodialysis patientswith secondary hyperparathyroidism. Nefrologia.2016;36(2):164-75. doi: 10.1016/j.nefro.2015.10.006.Epub 2015 Dec 3. PMID: 26654696.

3. Covic A, et al. Systematic review of the evidenceunderlying the association between mineralmetabolism disturbances and risk of all-causemortality, cardiovascular mortality, andcardiovascular events in chronic kidney disease.Nephrology, Dialysis, Transplantation, Volume 24,Issue 5, May 2009, Pages 1506–1523, https://doi.org/10.1093/ndt/gfn613

4. Slinin, Yelena; Foley, Robert N.; Collins, Allan.Calcium, Phosphorus, Parathyroid Hormone, andcardiovascular disease in Hemodialysis Patients:The USRDS Waves 1, 3, and 4 Study. Journal of theAmerican Society of Nephrology 16(6):p 1788-1793,June 2005. | DOI: 10.1681/ASN.2004040275

5. Covic A, Rastogi A. Hyperphosphatemia in patientswith ESRD: assessing the current evidence linkingoutcomes with treatment adherence. BMC Nephrol,14 (2013), p. 153

6. Pazianas M, Miller PD. Osteoporosis and ChronicKidney Disease-Mineral and Bone Disorder(CKD-MBD): Back to Basics. Am J Kidney Dis. 2021Oct;78(4):582-589. doi: 10.1053/j.ajkd.2020.12.024.Epub 2021 Mar 25. PMID: 33774081.

7. Mishra SK, Agarwal G, Kar DK, Gupta SK, MithalA, Rastad J. Unique clinical characteristics ofprimary hyperparathyroidism in India. Br J Surg.2001;88:708-14

8. Doufekias E., Segal A.Z., Kizer J.R.: Cardiogenic andAortogenic Brain Embolism. J Am Coll Cardiol 2008;51: pp. 1049-1059.

9. Pasch A., Block G.A., Bachtler M., Smith E.R., Jahnen-Dechent W., Arampatzis S., et. al.: Blood CalcificationPropensity Cardiovascular Events, and Survival inPatients Receiving Hemodialysis in the EVOLVETrial. Clin J Am Soc Nephrol 2017; 12: pp. 315.

10. 10) Slinin Y, et al. Calcium, phosphorus, parathyroidhormone, and cardiovascular disease in hemodialysispatients: the USRDS waves 1, 3, and 4 study. J Am SocNephrol, 16 (2005), pp. 1788-1793

11. Torregrosa JV, Bover J, Rodríguez Portillo M,González Parra E, Dolores Arenas M, Caravaca F,González Casaus ML, Martín-Malo A, Navarro-González JF, Lorenzo V, Molina P, Rodríguez M,Cannata Andia J. Recommendations of the SpanishSociety of Nephrology for the management of mineraland bone metabolism disorders in patients withchronic kidney disease: 2021 (SEN-MM). Nefrologia(Engl Ed). 2023 May 16:S2013-2514(23)00057-3. doi:10.1016/j.nefroe.2023.03.003. Epub ahead of print.PMID: 37202281.